Cardiovascular Medicine Book

http://www.fpnotebook.com/

Direct Acting Vasodilator

Aka: Direct Acting Vasodilator, Hydralazine, Apresoline, Diazoxide, Hyperstat, BiDil
  1. See Also
    1. Intravenous Antihypertensive
  2. Direct Acting Vasodilators IV
    1. Hydralazine (Apresoline)
      1. Dose: 10-40 mg IV/IM q4-6h
    2. Hydralazine with Isosorbide Dinitrate 37.5/20 (BiDil)
      1. Dose: 1-2 tablets PO tid
      2. For Class III CHF patients (esp. African American)
      3. Very expensive: $400/month
      4. Generic Drugs separately are $60/month
    3. Diazoxide (Hyperstat)
      1. Dose: 1-3 mg/kg up to 150 mg IV q5-15 min
    4. Nitroprusside Sodium (Nipride)
    5. Minoxidil (Loniten)

Hyperstat (C0699324)

Concepts Organic Chemical (T109) , Pharmacologic Substance (T121)
MSH D003981
English Hyperstat
Sources
Derived from the NIH UMLS (Unified Medical Language System)


Bidil (C0968130)

Concepts Organic Chemical (T109) , Pharmacologic Substance (T121)
MSH C431665
English Bidil, BiDil
Sources
Derived from the NIH UMLS (Unified Medical Language System)


Apresoline (C0699178)

Concepts Organic Chemical (T109) , Pharmacologic Substance (T121)
MSH D006830
English Apresoline, apresoline, Apressoline
Sources
Derived from the NIH UMLS (Unified Medical Language System)


Hydralazine (C0020223)

Definition (MSH) A direct-acting vasodilator that is used as an antihypertensive agent.
Definition (CSP) direct-acting vasodilator that is used as an antihypertensive.
Definition (NCI) A phthalazine derivative with antihypertensive effects. Hydralazine exerts its vasodilatory effects through modification of the contractile state of arterial vascular smooth muscle by altering intracellular calcium release, and interfering with smooth muscle cell calcium influx. This agent also causes inhibition of phosphorylation of myosin protein or chelation of trace metals required for smooth muscle contraction, thereby resulting in an increase in heart rate, stroke volume and cardiac output.
Concepts Organic Chemical (T109) , Pharmacologic Substance (T121)
MSH D006830
SnomedCT 22696000, 387125005
English Apressin, Hydralazine, Hydrallazin, Hydrazinophthalazine, hydralazine, 1(2H)-Phthalazinone, hydrazone, apressin, 1(2H)-Phthalazinone Hydrazone, Hydralazine [Chemical/Ingredient], hydrALAZINE, Apressinum, Hydralazine (product), Hydralazine (substance), HYDRALAZINE
Swedish Hydralazin
Czech hydralazin
Finnish Hydralatsiini
Russian APRESSIN, GIDRALAZIN, АПРЕССИН, ГИДРАЛАЗИН
Italian Apressina, Idrallazina, Idrazinoftalazina, Idralazina
Spanish Hidralazina, Hidralacina, hidralazina (producto), hidralazina (sustancia), hidralazina
Polish Hydralazyna
Japanese ヒドララジン, 塩酸ヒドララジン
French Hydralazine
German Hydralazin, Hydrallazin
Portuguese Hidralazina
Sources
Derived from the NIH UMLS (Unified Medical Language System)


Diazoxide (C0012022)

Definition (CSP) peripheral vasodilator that reduces blood pressure; diazoxide also has antidiuretic and hypoglycemic effects.
Definition (MSH) A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.
Definition (PDQ) A benzothiadiazine derivate with antihypertensive and hyperglycemic activities. Diazoxide increases membrane permeability to potassium ions in vascular smooth muscle, thereby stabilizing the membrane action potential and preventing vascular smooth muscle contraction; this results in peripheral vasodilatation and decreases in peripheral vascular resistance. This agent also inhibits insulin release by interacting with ATP-sensitive potassium channels of pancreatic islet beta-cells. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39290&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39290&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C428" NCI Thesaurus)
Definition (NCI) A benzothiadiazine derivate with antihypertensive and hyperglycemic activities. Diazoxide increases membrane permeability to potassium ions in vascular smooth muscle, thereby stabilizing the membrane action potential and preventing vascular smooth muscle contraction; this results in peripheral vasodilatation and decreases in peripheral vascular resistance. This agent also inhibits insulin release by interacting with ATP-sensitive potassium channels of pancreatic islet beta-cells.
Concepts Organic Chemical (T109) , Pharmacologic Substance (T121)
MSH D003981
SnomedCT 325291008, 318642007, 387328001, 58905004
English Diazoxide, 2H-1,2,4-Benzothiadiazine, 7-chloro-3-methyl-, 1,1-dioxide, 3-Methyl-7-chloro-1,2,4-benzothiadiazine 1,1-Dioxide, diazoxide, Diazoxide [cardiovascular use], Diazoxide [endocrine use], Diazoxide [endocrine use] (product), Diazoxide [cardiovascular use] (product), diazoxide (medication), Diazoxide [Chemical/Ingredient], diazoxides, Diazoxide (product), Diazoxide (substance), Diazoxide [cardiovascular use] (substance), Diazoxide [endocrine use] (substance), DIAZOXIDE
Swedish Diazoxid
Czech diazoxid
Finnish Diatsoksidi
Russian DIAZOKSID, ДИАЗОКСИД
Spanish diazóxido (uso cardiovascular) (producto), diazóxido [uso endocrino] (producto), diazóxido [uso endocrino], diazóxido (uso cardiovascular), diazóxido (producto), diazóxido (sustancia), diazóxido, Diazoxido, Diazóxido
Japanese ダイアゾキサイド, ジアゾキシド
Croatian DIAZOKSID
Polish Diazoksyd
French Diazoxide
German Diazoxid
Italian Diazossido
Portuguese Diazóxido
Sources
Derived from the NIH UMLS (Unified Medical Language System)


Navigation Tree